The impact of interfractional anatomical changes on the accumulated dose in carbon ion therapy of pancreatic cancer patients

2016 ◽  
Vol 119 (2) ◽  
pp. 319-325 ◽  
Author(s):  
Antonetta C. Houweling ◽  
Kyohei Fukata ◽  
Yoshiki Kubota ◽  
Hirofumi Shimada ◽  
Coen R.N. Rasch ◽  
...  
2016 ◽  
Vol 119 ◽  
pp. S402-S403
Author(s):  
A.C. Houweling ◽  
K. Fukata ◽  
Y. Kubota ◽  
H. Shimada ◽  
C.R.N. Rasch ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 163 ◽  
Author(s):  
Mikaela Dell’Oro ◽  
Michala Short ◽  
Puthenparampil Wilson ◽  
Eva Bezak

Introduction: Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact on overall survival. Hypoxia-activated prodrugs are the latest strategy to reintroduce oxygenation to radioresistant cells harbouring in pancreatic cancer. This paper reviews the current status of photon and particle radiation therapy for pancreatic cancer in combination with systemic therapies and hypoxia activators. Methods: The current effectiveness of management of pancreatic cancer was systematically evaluated from MEDLINE® database search in April 2019. Results: Limited published data suggest pancreatic cancer patients undergoing carbon ion therapy and proton therapy achieve a comparable median survival time (25.1 months and 25.6 months, respectively) and 1-year overall survival rate (84% and 77.8%). Inconsistencies in methodology, recording parameters and protocols have prevented the safety and technical aspects of particle therapy to be fully defined yet. Conclusion: There is an increasing requirement to tackle unmet clinical demands of pancreatic cancer, particularly the lack of synergistic therapies in the advancing space of radiation oncology.


2016 ◽  
Vol 11 (1) ◽  
Author(s):  
Julian Steitz ◽  
Patrick Naumann ◽  
Silke Ulrich ◽  
Matthias F. Haefner ◽  
Florian Sterzing ◽  
...  

2016 ◽  
Vol 119 ◽  
pp. S849 ◽  
Author(s):  
D. Panizza ◽  
S. Molinelli ◽  
A. Mirandola ◽  
G. Magro ◽  
S. Russo ◽  
...  

2017 ◽  
Vol 62 (8) ◽  
pp. 3051-3064 ◽  
Author(s):  
Antonetta C Houweling ◽  
Koen Crama ◽  
Jorrit Visser ◽  
Kyohei Fukata ◽  
Coen R N Rasch ◽  
...  

2016 ◽  
Vol 32 ◽  
pp. 49-50 ◽  
Author(s):  
D. Panizza ◽  
S. Molinelli ◽  
A. Mirandola ◽  
G. Magro ◽  
S. Russo ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Yang Li ◽  
Yoshiki Kubota ◽  
Masahiko Okamoto ◽  
Shintaro Shiba ◽  
Shohei Okazaki ◽  
...  

Abstract Background Daily anatomical deviations may distort the dose distribution in carbon ion radiotherapy (CIRT), which may cause treatment failure. Therefore, this study aimed to perform re-planning to maintain the dose coverage in patients with pancreatic cancer with passive scattering CIRT. Methods Eight patients with pancreatic cancer and 95 daily computed tomography (CT) sets were examined. Two types of adaptive plans based on new range compensators (RCs) (AP-1) and initial RCs (AP-2) were generated. In AP-2, each beam was optimized by manually adjusting the range shifter thickness and spread-out Bragg peak size to make dose reduction by < 3% of the original plan. Doses of the original plan with bone matching (BM) and tumor matching (TM) were examined for comparison. We calculated the accumulated dose using the contour and intensity-based deformable image registration algorithm. The dosimetric differences in respect to the original plan were compared between methods. Results Using TM and BM, mean ± standard deviations of daily CTV V95 (%) difference from the original plan was − 5.1 ± 6.2 and − 8.8 ± 8.8, respectively, but 1.2 ± 3.4 in AP-1 and − 0.5 ± 2.1 in AP-2 (P < 0.001). AP-1 and AP-2 enabled to maintain a satisfactory accumulated dose in all patients. The dose difference was 1.2 ± 2.8, − 2,1 ± 1.7, − 7.1 ± 5.2, and − 16.5 ± 15.0 for AP-1, AP-2, TM, and BM, respectively. However, AP-2 caused a dose increase in the duodenum, especially in the left–right beam. Conclusions The possible dose deterioration should be considered when performing the BM, even TM. Re-planning based on single beam optimization in passive scattering CIRT seems an effective and safe method of ensuring the treatment robustness in pancreatic cancer. Further study is necessary to spare healthy tissues, especially the duodenum.


Sign in / Sign up

Export Citation Format

Share Document